Literature DB >> 27559851

Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.

Shufeng Zhang1, Xiaohui Wang1, Zhimin Gu2, Li Wang1.   

Abstract

Survivin is an important oncogenic protein expressed highly in osteosarcoma. Here, we have shown that small molecule inhibitor YM155 potently suppressed survivin expression, inhibited cell growth, and induced apoptosis in osteosarcoma cells. Furthermore, we also showed that knock down of survivin by small interfering RNA strongly inhibited cell viability in two osteosarcoma cell lines, suggesting that suppression of survivin essentially contributes to YM155-mediated anticancer activity in osteosarcoma cells. Collectively, our study suggests that YM155 holds promise for patients with osteosarcoma.

Entities:  

Keywords:  YM155; apoptosis; osteosarcoma; survivin

Mesh:

Substances:

Year:  2016        PMID: 27559851     DOI: 10.1080/07357907.2016.1212205

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.368


  3 in total

1.  Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Authors:  Nicolas J Llosa; Kenneth R Cooke; Allen R Chen; Christopher J Gamper; Orly R Klein; Elias T Zambidis; Brandon Luber; Gary Rosner; Nicholas Siegel; Mary Jo Holuba; Nancy Robey; Masanori Hayashi; Richard J Jones; Ephraim Fuchs; Matthias Holdhoff; David M Loeb; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-12       Impact factor: 5.742

2.  Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response.

Authors:  Elizabeth A Mazzio; Charles A Lewis; Rashid Elhag; Karam F Soliman
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 3.395

3.  Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment.

Authors:  Christian Vay; Philipp M Schlünder; Levent Dizdar; Irene Esposito; Markus P H Ghadimi; Wolfram T Knoefel; Andreas Krieg
Journal:  J Cancer Res Clin Oncol       Date:  2021-12-03       Impact factor: 4.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.